Trials / Completed
CompletedNCT07056309
A Study of Remternetug (LY3372993) in Healthy Participants
A Study on Pharmacokinetics of Remternetug Administered Subcutaneously Through an Autoinjector Versus Prefilled Syringe in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remternetug (Test) | Administered SC |
| DRUG | Remternetug (Reference) | Administered SC |
Timeline
- Start date
- 2025-06-24
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
- First posted
- 2025-07-09
- Last updated
- 2026-01-23
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07056309. Inclusion in this directory is not an endorsement.